REVISE: Re-Evaluating the Inhibition of Stress Erosions in the ICU: a randomised trial protocol
Files
(Published version)
Date
2023
Authors
Deane, A.M.
Alhazzani, W.
Guyatt, G.
Finfer, S.
Marshall, J.C.
Myburgh, J.
Zytaruk, N.
Hardie, M.
Saunders, L.
Knowles, S.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
BMJ Open, 2023; 13(11):1-11
Statement of Responsibility
Adam M Deane ... Marianne J Chapman ... Alexis Poole ... et al.
Conference Name
Abstract
Introduction: The Re-Evaluating the Inhibition of Stress Erosions (REVISE) Trial aims to determine the impact of the proton pump inhibitor pantoprazole compared with placebo on clinically important upper gastrointestinal (GI) bleeding in the intensive care unit (ICU), 90-day mortality and other endpoints in critically ill adults. The objective of this report is to describe the rationale, methodology, ethics and management of REVISE. Methods and analysis: REVISE is an international, randomised, concealed, stratified, blinded parallelgroup individual patient trial being conducted in ICUs in Canada, Australia, Saudi Arabia, UK, US, Kuwait, Pakistan and Brazil. Patients≥18 years old expected to remain invasively mechanically ventilated beyond the calendar day after enrolment are being randomised to either 40 mg pantoprazole intravenously or an identical placebo daily while mechanically ventilated in the ICU. The primary efficacy outcome is clinically important upper GI bleeding within 90 days of randomisation. The primary safety outcome is 90-day all-cause mortality. Secondary outcomes include rates of ventilator-associated pneumonia, Clostridioides difficile infection, new renal replacement therapy, ICU and hospital mortality, and patient-important GI bleeding. Tertiary outcomes are total red blood cells transfused, peak serum creatinine level in the ICU, and duration of mechanical ventilation, ICU and hospital stay. The sample size is 4800 patients; one interim analysis was conducted after 2400 patients had complete 90-day follow-up; the Data Monitoring Committee recommended continuing the trial.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.